PCRX Q2 2017 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q2 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$71M+1.9% YoY

Gross Profit

$47M66.4% margin

Operating Income

-$16M-22.2% margin

Net Income

-$20M-27.8% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+2.4%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

-$1M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$606M

Total Liabilities

$345M

Stockholders' Equity

$261M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$70M	+1.9%
Gross Profit	$47M	$47M	+1.2%
Operating Income	-$16M	-$6M	-144.9%
Net Income	-$20M	-$8M	-148.1%